Status: Finalised First registered on: 11/03/2015
Last updated on: 16/01/2019
1. Study identification
EU PAS Register NumberEUPAS8840
Official titleDose response curves for patients prescribed small & large particle ICS formulation: an observational evaluation of the comparative effect of ICS dose on asthma control achieved in real-life UK patients managed on extrafine hydrofluoroalkane beclomethasone, ciclesonide, fluticasone propionate, or Clenil
Study title acronym
Study typeObservational study
Brief description of the studyAims to evaluate the relationship between ICS dose and treatment outcomes for patients prescribed small or large particle formulation by comparing asthma control outcomes associated with different doses of each ICS in order to create real-life dose-response curves. The outcomes evaluated are change in severe exacerbation rates, change in percent predicted PEF and change in average daily SABA dose
Was this study requested by a regulator?No
Is the study required by a Risk Management Plan (RMP)? Not applicable
Regulatory procedure number (RMP Category 1 and 2 studies only)
Other study registration identification numbers and URLs as applicable
2. Research centres and Investigator details
Coordinating study entity
Centre to which the investigator belongsOPRI Pte Ltd
Department/Research groupObservational and Pragmatic Research Institute Pte Ltd
Organisation/affiliationOPRI Pte Ltd
Website/Homepagewww.opri.sg
Details of (Primary) lead investigator
Title Professor
Last name Price
First name David
Is this study being carried out with the collaboration of a research network?
No
Other centres where this study is being conducted
Not applicable (single centre)

Countries in which this study is being conducted
National study

United Kingdom
3. Study timelines: initial administrative steps, progress reports and final report
PlannedActual
Date when funding contract was signed01/02/2013
Start date of data collection01/04/2013
Start date of data analysis
Date of interim report, if expected
Date of final study report05/11/2014
4. Sources of funding
Please provide estimates of the percentage of funding by source for this study
Names(s)Approximate % funding
Pharmaceutical companiesTeva100
Charities
Government body
Research councils
EU funding scheme
5. Contact details for enquiries
Scientific Enquiries
Title Professor
Last name Price
First name David
Address line 12 Changi Business Park Avenue 1
Address line 2Level 2 
Address line 3 
CitySingapore 
Postcode486015 
CountrySingapore
Phone number (incl. country code)6568097251 
Alternative phone number 
Fax number (incl. country code) 
Email address david@rirl.org
Public Enquiries
Title Professor 
Last name Price 
First name David 
Address line 12 Changi Business Park Avenue 1 
Address line 2Level 2 
Address line 3 
CitySingapore 
Postcode486015 
CountrySingapore 
Phone number (incl. country code)6568097251 
Alternative phone number 
Fax number (incl. country code) 
Email address dprice@opri.sg 
Top